• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.

作者信息

Kalac Matko, Jain Salvia, Tam Constantine S, Xiao Zhengrui, Montanari Francesca, Kanakry Jennifer, Huber Bryan D, Goldfinger Mendel, O'Connor Owen A, Marchi Enrica

机构信息

Department of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Department of Hematology and Oncology, University of California, Irvine, CA.

出版信息

Blood Adv. 2023 Jul 25;7(14):3760-3763. doi: 10.1182/bloodadvances.2022009445.

DOI:10.1182/bloodadvances.2022009445
PMID:36790924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10368677/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3783/10368677/4336c9c900fe/BLOODA_ADV-2022-009445-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3783/10368677/4336c9c900fe/BLOODA_ADV-2022-009445-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3783/10368677/4336c9c900fe/BLOODA_ADV-2022-009445-gr1.jpg

相似文献

1
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.阿扎胞苷与罗米地辛联合治疗外周T细胞淋巴瘤患者的真实世界经验。
Blood Adv. 2023 Jul 25;7(14):3760-3763. doi: 10.1182/bloodadvances.2022009445.
2
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.罗米地辛治疗复发或难治性外周和皮肤 T 细胞淋巴瘤：一项全国多中心观察性研究的真实数据。
Hematol Oncol. 2019 Dec;37(5):569-577. doi: 10.1002/hon.2691. Epub 2019 Nov 25.
3
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.联合口服 5-氮杂胞苷和罗米地辛对 PTCL 患者具有高度疗效：一项多中心 2 期研究。
Blood. 2021 Apr 22;137(16):2161-2170. doi: 10.1182/blood.2020009004.
4
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.罗米地辛治疗复发/难治性外周T细胞淋巴瘤：关键研究更新显示疗效持久。
J Hematol Oncol. 2014 Jan 23;7:11. doi: 10.1186/1756-8722-7-11.
5
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.罗米地辛联合环磷酰胺、多柔比星、长春新碱和泼尼松用于既往未接受治疗的外周T细胞淋巴瘤患者：一项非随机1b/2期研究
Lancet Haematol. 2015 Apr;2(4):e160-5. doi: 10.1016/S2352-3026(15)00023-X. Epub 2015 Mar 17.
6
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.罗米地辛用于治疗外周T细胞淋巴瘤。
Oncologist. 2015 Sep;20(9):1084-91. doi: 10.1634/theoncologist.2015-0043. Epub 2015 Jun 22.
7
Failure of Romidepsin to Treat Relapsed/Refractory Peripheral T-Cell Lymphoma in Children: A Single-center Experience.罗米地辛治疗儿童复发/难治性外周T细胞淋巴瘤失败：单中心经验
J Pediatr Hematol Oncol. 2021 Jul 1;43(5):e745-e748. doi: 10.1097/MPH.0000000000001824.
8
Romidepsin: in the treatment of T-cell lymphoma.罗米地辛：治疗 T 细胞淋巴瘤。
Drugs. 2011 Jul 30;71(11):1469-80. doi: 10.2165/11207170-000000000-00000.
9
Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials.罗米地辛对60岁及以上复发或难治性外周T细胞淋巴瘤（PTCL）患者有效且耐受性良好：来自2期试验的分析
Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 5):17-8.
10
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).罗米地辛联合CHOP方案与CHOP方案治疗初治外周T细胞淋巴瘤患者的疗效比较：Ro-CHOP III期研究（由LYSA组织开展）结果
J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29.

引用本文的文献

1
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.度维利塞和罗米地辛用于复发/难治性外周和皮肤T细胞淋巴瘤的真实世界证据。
Blood Adv. 2025 Aug 26;9(16):4286-4305. doi: 10.1182/bloodadvances.2025016347.
2
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.预测复发/难治性成熟T细胞和NK细胞淋巴瘤的最佳治疗方案：一项全球PETAL联盟研究。
Br J Haematol. 2025 Jun;206(6):1664-1677. doi: 10.1111/bjh.20063. Epub 2025 May 1.
3
Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.

本文引用的文献

1
Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma.5-氮杂胞苷作为挽救性化疗治疗血管免疫母细胞性 T 细胞淋巴瘤的真实世界疗效。
Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):e972-e980. doi: 10.1016/j.clml.2022.07.009. Epub 2022 Jul 17.
2
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.靶向 T 细胞淋巴瘤表观基因组诱导细胞死亡、癌症睾丸抗原、免疫调节信号通路。
Mol Cancer Ther. 2021 Aug;20(8):1422-1430. doi: 10.1158/1535-7163.MCT-20-0377. Epub 2021 Jun 9.
3
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
T细胞恶性肿瘤的管理：从 bench 到床边的表观遗传生物学靶向治疗
CA Cancer J Clin. 2025 Jul-Aug;75(4):282-307. doi: 10.3322/caac.70001. Epub 2025 Apr 15.
4
Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas.用于外周T细胞淋巴瘤的组蛋白去乙酰化酶抑制剂
Cancers (Basel). 2024 Sep 30;16(19):3359. doi: 10.3390/cancers16193359.
5
Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation.一名患有TET2突变的难治性外周T细胞淋巴瘤患者对阿扎胞苷的反应
Cureus. 2024 Jul 26;16(7):e65416. doi: 10.7759/cureus.65416. eCollection 2024 Jul.
6
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.复发/难治性外周 T 细胞淋巴瘤的新型临床风险分层和治疗策略。
J Hematol Oncol. 2024 Jun 1;17(1):38. doi: 10.1186/s13045-024-01560-7.
7
Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.超越化疗：淋巴增殖性疾病治疗的现状与未来展望
Biomedicines. 2024 Apr 29;12(5):977. doi: 10.3390/biomedicines12050977.
8
Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.结外外周 T 细胞淋巴瘤的过去、现在和未来治疗方法。
Haematologica. 2023 Dec 1;108(12):3211-3226. doi: 10.3324/haematol.2021.280275.
联合口服 5-氮杂胞苷和罗米地辛对 PTCL 患者具有高度疗效：一项多中心 2 期研究。
Blood. 2021 Apr 22;137(16):2161-2170. doi: 10.1182/blood.2020009004.
4
The peripheral T-cell lymphomas: an unusual path to cure.外周T细胞淋巴瘤：一条不同寻常的治愈之路。
Lancet Haematol. 2020 Oct;7(10):e765-e771. doi: 10.1016/S2352-3026(20)30207-6.
5
Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials.新型疗法和临床试验治疗外周 T 细胞淋巴瘤患者的生存获益。
Hematol Oncol. 2020 Feb;38(1):51-58. doi: 10.1002/hon.2705. Epub 2019 Dec 29.
6
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.口服 5-氮杂胞苷和罗米地辛在 PTCL 患者中表现出显著的活性：一项多中心 1 期研究。
Blood. 2019 Oct 24;134(17):1395-1405. doi: 10.1182/blood.2019001285.
7
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.在T细胞淋巴瘤的临床前模型中，低甲基化剂与组蛋白去乙酰化酶抑制剂联合使用可产生显著的协同作用。
Br J Haematol. 2015 Oct;171(2):215-226. doi: 10.1111/bjh.13566. Epub 2015 Jul 20.
8
Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.外周 T 细胞淋巴瘤患者首次复发或进展后的生存情况：疾病谱和罕见的长期幸存者。
J Clin Oncol. 2013 Jun 1;31(16):1970-6. doi: 10.1200/JCO.2012.44.7524. Epub 2013 Apr 22.
9
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.外周 T 细胞淋巴瘤中反复出现的 TET2 突变与 TFH 样特征和不良临床参数相关。
Blood. 2012 Aug 16;120(7):1466-9. doi: 10.1182/blood-2012-02-408542. Epub 2012 Jul 3.
10
TET2 and DNMT3A mutations in human T-cell lymphoma.人类T细胞淋巴瘤中的TET2和DNMT3A突变
N Engl J Med. 2012 Jan 5;366(1):95-6. doi: 10.1056/NEJMc1111708.